About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

379188 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 07/24/2021.
 Menu
This website is for US healthcare professionals
close-icon

Log In to Bolder Science

logo-iconLog in with Doximity
or
Forgot Password

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

logo-iconLog in with Doximity
or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

Previous Next skip
Our Science

idecabtagene vicleucel (ide-cel; bb2121; Anti-BCMA CAR T Cells)

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

 

Proposed Mechanism of Action

Ide-cel is an investigational chimeric antigen receptor (CAR) T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells.1,2?The ide-cel CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, CD3-zeta T-cell activation domain, and a 4-1BB domain hypothesized to increase T-cell activation, proliferation, and persistence.1,3-5?Ide-cel CAR T cells are proposed to recognize and bind BCMA on the surface of plasma cells leading to apoptosis.6,7

Ide-cel Proposed Mechanism of Action

Ide-cel, an investigational CAR T therapy, is proposed to target BCMA on plasma cells.

An investigational anti-BCMA (B-cell maturation antigen) CAR-T cell therapy that is being developed for the treatment of multiple myeloma by Celgene in collaboration with bluebird bio.